Development of an LDL Receptor-Targeted Peptide Susceptible to Facilitate the Brain Access of Diagnostic or Therapeutic Agents

André, Séverine; Larbanoix, Lionel; Verteneuil, Sébastien; Stanicki, Dimitri; Nonclercq, Denis; Vander Elst, Luce; Laurent, Sophie; Muller, Robert; Burtea, Carmen

doi:10.3390/biology9070161

Article (Scientific journals)

Development of an LDL Receptor-Targeted Peptide Susceptible to Facilitate the Brain Access of Diagnostic or Therapeutic Agents

André, Séverine; Larbanoix, Lionel; Verteneuil, Sébastien et al.

2020 • In Biology

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/249815

DOI
10.3390/biology9070161

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

biology-09-00161.pdf

Publisher postprint (5.28 MB)

Download

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Disciplines :

Biochemistry, biophysics & molecular biology

Author, co-author :

André, Séverine; Université de Mons - UMONS

Larbanoix, Lionel; Center for Microscopy and Molecular Imaging

Verteneuil, Sébastien ; Université de Liège - ULiège > GIGA

Stanicki, Dimitri; Université de Mons - UMONS

Nonclercq, Denis; Université de Mons - UMONS

Vander Elst, Luce; Université de Mons - UMONS

Laurent, Sophie; Université de Mons - UMONS

Muller, Robert; Université de Mons - UMONS

Burtea, Carmen; Université de Mons - UMONS

Language :

English

Title :

Development of an LDL Receptor-Targeted Peptide Susceptible to Facilitate the Brain Access of Diagnostic or Therapeutic Agents

Publication date :

2020

Journal title :

Biology

eISSN :

2079-7737

Publisher :

Multidisciplinary Digital Publishing Institute (MDPI), Switzerland

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 29 July 2020

Statistics

Number of views

60 (8 by ULiège)

Number of downloads

43 (6 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Neuwelt, E.A.; Bauer, B.; Fahlke, C.; Fricker, G.; Iadecola, C.; Janigro, D.; Leybaert, L.; Molnár, Z.; O’Donnell, M.E.; Povlishock, J.T.; et al. Engaging neuroscience to advance translational research in brain barrier biology. Nat. Rev. Neurosci. 2011, 12, 169–182. [CrossRef] [PubMed]
Chen, Y.; Liu, L. Modern methods for delivery of drugs across the blood-brain barrier. Adv. Drug Deliv. Rev. 2012, 64, 640–665. [CrossRef]
Pardridge, W.M. Blood-brain barrier delivery. Drug Discov. Today 2007, 12, 54–61. [CrossRef] [PubMed]
Gabathuler, R. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol. Dis. 2010, 37, 48–57. [CrossRef] [PubMed]
Illum, L. Nasal drug delivery-recent developments and future prospects. J. Control. Release Off. J. Control. Release Soc. 2012, 161, 254–263. [CrossRef] [PubMed]
Brasnjevic, I.; Steinbusch, H.W.M.; Schmitz, C.; Martinez-Martinez, P. European NanoBioPharmaceutics Research Initiative Delivery of peptide and protein drugs over the blood-brain barrier. Prog. Neurobiol. 2009, 87, 212–251. [CrossRef]
Jones, A.R.; Shusta, E.V. Blood-brain barrier transport of therapeutics via receptor-mediation. Pharm. Res. 2007, 24, 1759–1771. [CrossRef]
Fang, F.; Zou, D.; Wang, W.; Yin, Y.; Yin, T.; Hao, S.; Wang, B.; Wang, G.; Wang, Y. Non-invasive approaches for drug delivery to the brain based on the receptor mediated transport. Mater. Sci. Eng. C Mater. Biol. Appl. 2017, 76, 1316–1327. [CrossRef]
Go, G.-W.; Mani, A. Low-density lipoprotein receptor (LDLR) family orchestrates cholesterol homeostasis. Yale J. Biol. Med. 2012, 85, 19–28.
Dehouck, B.; Fenart, L.; Dehouck, M.P.; Pierce, A.; Torpier, G.; Cecchelli, R. A new function for the LDL receptor: Transcytosis of LDL across the blood-brain barrier. J. Cell Biol. 1997, 138, 877–889. [CrossRef]
Candela, P.; Gosselet, F.; Miller, F.; Buee-Scherrer, V.; Torpier, G.; Cecchelli, R.; Fenart, L. Physiological pathway for low-density lipoproteins across the blood-brain barrier: Transcytosis through brain capillary endothelial cells in vitro. Endothel. J. Endothel. Cell Res. 2008, 15, 254–264. [CrossRef] [PubMed]
Molino, Y.; David, M.; Varini, K.; Jabès, F.; Gaudin, N.; Fortoul, A.; Bakloul, K.; Masse, M.; Bernard, A.; Drobecq, L.; et al. Use of LDL receptor-targeting peptide vectors for in vitro and in vivo cargo transport across the blood-brain barrier. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 2017, 31, 1807–1827. [CrossRef] [PubMed]
Zhang, Y.; Chen, K.; Sloan, S.A.; Bennett, M.L.; Scholze, A.R.; O’Keeffe, S.; Phatnani, H.P.; Guarnieri, P.; Caneda, C.; Ruderisch, N.; et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J. Neurosci. Off. J. Soc. Neurosci. 2014, 34, 11929–11947. [CrossRef] [PubMed]
Zhang, Y.; Sloan, S.A.; Clarke, L.E.; Caneda, C.; Plaza, C.A.; Blumenthal, P.D.; Vogel, H.; Steinberg, G.K.; Edwards, M.S.B.; Li, G.; et al. Purification and Characterization of Progenitor and Mature Human Astrocytes Reveals Transcriptional and Functional Differences with Mouse. Neuron 2016, 89, 37–53. [CrossRef] [PubMed]
Vanlandewijck, M.; He, L.; Mäe, M.A.; Andrae, J.; Ando, K.; Del Gaudio, F.; Nahar, K.; Lebouvier, T.; Laviña, B.; Gouveia, L.; et al. A molecular atlas of cell types and zonation in the brain vasculature. Nature 2018, 554, 475–480. [CrossRef] [PubMed]
He, L.; Vanlandewijck, M.; Mäe, M.A.; Andrae, J.; Ando, K.; Del Gaudio, F.; Nahar, K.; Lebouvier, T.; Laviña, B.; Gouveia, L.; et al. Single-cell RNA sequencing of mouse brain and lung vascular and vessel-associated cell types. Sci. Data 2018, 5, 180160. [CrossRef] [PubMed]
Pulgar, V.M. Transcytosis to Cross the Blood Brain Barrier, New Advancements and Challenges. Front. Neurosci. 2018, 12, 1019. [CrossRef] [PubMed]
Smith, G.P.; Petrenko, V.A. Phage Display. Chem. Rev. 1997, 97, 391–410. [CrossRef]
Kristensen, M.; Brodin, B. Routes for Drug Translocation Across the Blood-Brain Barrier: Exploiting Peptides as Delivery Vectors. J. Pharm. Sci. 2017. [CrossRef]
Thayer, A.M. Improving peptides. Chem. Eng. News Arch. 2011, 89, 13–20. [CrossRef]
Larbanoix, L.; Burtea, C.; Laurent, S.; Van Leuven, F.; Toubeau, G.; Vander Elst, L.; Muller, R.N. Potential amyloid plaque-specific peptides for the diagnosis of Alzheimer’s disease. Neurobiol. Aging 2010, 31, 1679–1689. [CrossRef] [PubMed]
Zhou, P.; Jin, B.; Li, H.; Huang, S.-Y. HPEPDOCK: A web server for blind peptide-protein docking based on a hierarchical algorithm. Nucleic Acids Res. 2018, 46, W443–W450. [CrossRef] [PubMed]
André, S.; Ansciaux, E.; Saidi, E.; Larbanoix, L.; Stanicki, D.; Nonclercq, D.; Vander Elst, L.; Laurent, S.; Muller, R.N.; Burtea, C. Validation by Magnetic Resonance Imaging of the Diagnostic Potential of a Heptapeptide-Functionalized Imaging Probe Targeted to Amyloid-β and Able to Cross the Blood-Brain Barrier. J. Alzheimers Dis. JAD 2017, 60, 1547–1565. [CrossRef] [PubMed]
Burtea, C.; Laurent, S.; Port, M.; Lancelot, E.; Ballet, S.; Rousseaux, O.; Toubeau, G.; Vander Elst, L.; Corot, C.; Muller, R.N. Magnetic resonance molecular imaging of vascular cell adhesion molecule-1 expression in inflammatory lesions using a peptide-vectorized paramagnetic imaging probe. J. Med. Chem. 2009, 52, 4725–4742. [CrossRef] [PubMed]
Stanicki, D.; Boutry, S.; Laurent, S.; Wacheul, L.; Nicolas, E.; Crombez, D.; Vander Elst, L.; Lafontaine, D.L.J.; Muller, R.N. Carboxy-silane coated iron oxide nanoparticles: A convenient platform for cellular and small animal imaging. J. Mater. Chem. B 2013, 2, 387–397. [CrossRef] [PubMed]
Bridot, J.-L.; Stanicki, D.; Laurent, S.; Boutry, S.; Gossuin, Y.; Leclère, P.; Lazzaroni, R.; Vander Elst, L.; Muller, R.N. New carboxysilane-coated iron oxide nanoparticles for nonspecific cell labelling. Contrast Media Mol. Imaging 2013, 8, 466–474. [CrossRef]
Mireles, L.-K.; Sacher, E.; Yahia, L.; Laurent, S.; Stanicki, D. A comparative physicochemical, morphological and magnetic study of silane-functionalized superparamagnetic iron oxide nanoparticles prepared by alkaline coprecipitation. Int. J. Biochem. Cell Biol. 2016, 75, 203–211. [CrossRef]
Burtea, C.; Laurent, S.; Mahieu, I.; Larbanoix, L.; Roch, A.; Port, M.; Rousseaux, O.; Ballet, S.; Murariu, O.; Toubeau, G.; et al. In vitro biomedical applications of functionalized iron oxide nanoparticles, including those not related to magnetic properties. Contrast Media Mol. Imaging 2011, 6, 236–250. [CrossRef]
Dupont, W.; Plummer, W. Power and Sample Size Calculations for studies Involving Linear Regression. Control. Clin. Trials 1998, 19, 589–601. [CrossRef]
Burtea, C.; Ballet, S.; Laurent, S.; Rousseaux, O.; Dencausse, A.; Gonzalez, W.; Port, M.; Corot, C.; Vander Elst, L.; Muller, R.N. Development of a magnetic resonance imaging protocol for the characterization of atherosclerotic plaque by using vascular cell adhesion molecule-1 and apoptosis-targeted ultrasmall superparamagnetic iron oxide derivatives. Arterioscler. Thromb. Vasc. Biol. 2012, 32, e36–e48. [CrossRef]
Burtea, C.; Laurent, S.; Crombez, D.; Delcambre, S.; Sermeus, C.; Millard, I.; Rorive, S.; Flamez, D.; Beckers, M.-C.; Salmon, I.; et al. Development of a peptide-functionalized imaging nanoprobe for the targeting of (FXYD2)γa as a highly specific biomarker of pancreatic beta cells. Contrast Media Mol. Imaging 2015, 10, 398–412. [CrossRef] [PubMed]
Ansciaux, E.; Burtea, C.; Laurent, S.; Crombez, D.; Nonclercq, D.; Vander Elst, L.; Muller, R.N. In vitro and in vivo characterization of several functionalized ultrasmall particles of iron oxide, vectorized against amyloid plaques and potentially able to cross the blood-brain barrier: Toward earlier diagnosis of Alzheimer’s disease by molecular imaging. Contrast Media Mol. Imaging 2015, 10, 211–224. [CrossRef] [PubMed]
Burtea, C.; Laurent, S.; Sanli, T.; Fanfone, D.; Devalckeneer, A.; Sauvage, S.; Beckers, M.-C.; Rorive, S.; Salmon, I.; Vander Elst, L.; et al. Screening for peptides targeted to IL-7Rα for molecular imaging of rheumatoid arthritis synovium. Arthritis Res. Ther. 2016, 18, 230. [CrossRef] [PubMed]
Huang, S.; Henry, L.; Ho, Y.K.; Pownall, H.J.; Rudenko, G. Mechanism of LDL binding and release probed by structure-based mutagenesis of the LDL receptor. J. Lipid Res. 2010, 51, 297–308. [CrossRef]
Elliott, D.A.; Halliday, G.M.; Garner, B. Apolipoprotein-E forms dimers in human frontal cortex and hippocampus. BMC Neurosci. 2010, 11, 23. [CrossRef]
Al-Ali, H.; Khachfe, H.M. The N-terminal domain of apolipoprotein B-100: Structural characterization by homology modeling. BMC Biochem. 2007, 8, 12. [CrossRef] [PubMed]
Lesk, A.M. Introduction to Protein Sciences-Architecture, Function, Genomics; Oxford University Press: New York, NY, USA, 2006.
Zhao, Z.; Michaely, P. The role of calcium in lipoprotein release by the low-density lipoprotein receptor. Biochemistry 2009, 48, 7313–7324. [CrossRef] [PubMed]
Moussard, C. La Biochimie-Tome 1. Biochimie Structurale et Métabolique-Médecine Pharmacie, Sciences; DeBoeck Université: Paris, Bruxelles, 1999.
Uniprot APOB-Apolipoprotein B-100 Precursor-Homo Sapiens (Human)-APOB Gene & Protein. Available online: https://www.uniprot.org/uniprot/P04114#sequences (accessed on 11 April 2019).
Uniprot APOE-Apolipoprotein E Precursor-Homo Sapiens (Human)-APOE Gene & Protein. Available online: https://www.uniprot.org/uniprot/P02649#sequences (accessed on 11 April 2019).
Alves, A.C.; Etxebarria, A.; Soutar, A.K.; Martin, C.; Bourbon, M. Novel functional APOB mutations outside LDL-binding region causing familial hypercholesterolaemia. Hum. Mol. Genet. 2014, 23, 1817–1828. [CrossRef] [PubMed]
Prévost, M.; Raussens, V. Apolipoprotein E-low density lipoprotein receptor binding: Study of protein-protein interaction in rationally selected docked complexes. Proteins 2004, 55, 874–884. [CrossRef]
Lalazar, A.; Weisgraber, K.H.; Rall, S.C.; Giladi, H.; Innerarity, T.L.; Levanon, A.Z.; Boyles, J.K.; Amit, B.; Gorecki, M.; Mahley, R.W. Site-specific mutagenesis of human apolipoprotein E. Receptor binding activity of variants with single amino acid substitutions. J. Biol. Chem. 1988, 263, 3542–3545.
Blanco, F.J.; Villegas, S.; Benítez, S.; Bancells, C.; Diercks, T.; Ordóñez-Llanos, J.; Sánchez-Quesada, J.L. 2D-NMR reveals different populations of exposed lysine residues in the apoB-100 protein of electronegative and electropositive fractions of LDL particles. J. Lipid Res. 2010, 51, 1560–1565. [CrossRef] [PubMed]
Yamamoto, H.; Ehling, M.; Kato, K.; Kanai, K.; van Lessen, M.; Frye, M.; Zeuschner, D.; Nakayama, M.; Vestweber, D.; Adams, R.H. Integrin β1 controls VE-cadherin localization and blood vessel stability. Nat. Commun. 2015, 6, 6429. [CrossRef] [PubMed]
Pelton, J.C.; Wright, C.E.; Leitges, M.; Bautch, V.L. Multiple endothelial cells constitute the tip of developing blood vessels and polarize to promote lumen formation. Dev. Camb. Engl. 2014, 141, 4121–4126. [CrossRef]
Bolte, S.; Cordelières, F.P. A guided tour into subcellular colocalization analysis in light microscopy. J. Microsc. 2006, 224, 213–232. [CrossRef] [PubMed]
van de Sluis, B.; Wijers, M.; Herz, J. News on the molecular regulation and function of hepatic low-density lipoprotein receptor and LDLR-related protein 1. Curr. Opin. Lipidol. 2017, 28, 241–247. [CrossRef]
Sukhbaatar, N.; Weichhart, T. Iron Regulation: Macrophages in Control. Pharm. Basel Switz. 2018, 11, 137. [CrossRef]
Yu, Q.; Xiong, X.-Q.; Zhao, L.; Xu, T.-T.; Bi, H.; Fu, R.; Wang, Q.-H. Biodistribution and Toxicity Assessment of Superparamagnetic Iron Oxide Nanoparticles In Vitro and In Vivo. Curr. Med. Sci. 2018, 38, 1096–1102. [CrossRef]
Gaillard, P.J.; Appeldoorn, C.C.M.; Dorland, R.; van Kregten, J.; Manca, F.; Vugts, D.J.; Windhorst, B.; van Dongen, G.A.M.S.; de Vries, H.E.; Maussang, D.; et al. Pharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of glutathione pegylated liposomal doxorubicin (2B3-101). PLoS ONE 2014, 9, e82331. [CrossRef]
Shanehsazzadeh, S.; Oghabian, M.A.; Lahooti, A.; Abdollahi, M.; Abolghasem Haeri, S.; Amanlou, M.; Daha, F.J.; Allen, B.J. Estimated background doses of [67Ga]-DTPA-USPIO in normal Balb/c mice as a potential therapeutic agent for liver and spleen cancers. Nucl. Med. Commun. 2013, 34, 915–925. [CrossRef]
Brunnquell, C.L.; Hernandez, R.; Graves, S.A.; Smit-Oistad, I.; Nickles, R.J.; Cai, W.; Meyerand, M.E.; Suzuki, M. Uptake and retention of manganese contrast agents for PET and MRI in the rodent brain. Contrast Media Mol. Imaging 2016, 11, 371–380. [CrossRef]
Calvo, P.; Gouritin, B.; Villarroya, H.; Eclancher, F.; Giannavola, C.; Klein, C.; Andreux, J.P.; Couvreur, P. Quantification and localization of PEGylated polycyanoacrylate nanoparticles in brain and spinal cord during experimental allergic encephalomyelitis in the rat. Eur. J. Neurosci. 2002, 15, 1317–1326. [CrossRef] [PubMed]
Ku, S.; Yan, F.; Wang, Y.; Sun, Y.; Yang, N.; Ye, L. The blood-brain barrier penetration and distribution of PEGylated fluorescein-doped magnetic silica nanoparticles in rat brain. Biochem. Biophys. Res. Commun. 2010, 394, 871–876. [CrossRef] [PubMed]
Li, J.; Feng, L.; Fan, L.; Zha, Y.; Guo, L.; Zhang, Q.; Chen, J.; Pang, Z.; Wang, Y.; Jiang, X.; et al. Targeting the brain with PEG-PLGA nanoparticles modified with phage-displayed peptides. Biomaterials 2011, 32, 4943–4950. [CrossRef] [PubMed]
Gopalraj, R.K.; Zhu, H.; Kelly, J.F.; Mendiondo, M.; Pulliam, J.F.; Bennett, D.A.; Estus, S. Genetic association of low density lipoprotein receptor and Alzheimer’s disease. Neurobiol. Aging 2005, 26, 1–7. [CrossRef] [PubMed]
Castellano, J.M.; Deane, R.; Gottesdiener, A.J.; Verghese, P.B.; Stewart, F.R.; West, T.; Paoletti, A.C.; Kasper, T.R.; DeMattos, R.B.; Zlokovic, B.V.; et al. Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis. Proc. Natl. Acad. Sci. USA 2012, 109, 15502–15507. [CrossRef]